The importance of targeting TP53 in AML and agents being explored

An analysis of TP53 mutation in AML and HR-MDSПодробнее

Challenges in treating patients with TP53-mutated AML and future outlooksПодробнее

Promising agents in AML: menin inhibitors & magrolimab in TP53-mutated AMLПодробнее

A Drug to Finally Benefit Patients with TP53 Mutant AML? | David Sallman | ASH 2021 #AMLПодробнее

Targeting p53 in MDSПодробнее

Improving treatment for patients with TP53-mutated myeloid malignanciesПодробнее

Significance of p53 mutations in AMLПодробнее

Dr. Pemmaraju on the Challenges of Targeting TP53 Mutations in MDS/AMLПодробнее

TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic PrinciplesПодробнее

The challenges of treating patients with MPNs who possess a TP53 mutationПодробнее

Treatment approaches for patients with TP53m AML ineligible for high intensity chemotherapyПодробнее

Challenges in Treating TP53-Mutated AML, Hope on the HorizonПодробнее

TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclaxПодробнее

Novel strategies to target P53-mutant hematological malignanciesПодробнее

The association between prior exposure to lenalidomide and TP53-mutated AML/MDSПодробнее

Novel Therapies in Myeloid NeoplasmsПодробнее

The prognostic impact of TP53 and IgHV status in the era of targeted therapies in CLLПодробнее

Outcomes of TP53-mutant AML with venetoclax and decitabineПодробнее

Tolerability and efficacy of magrolimab plus azacitidine in TP53-mutated AML patientsПодробнее